Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.39 USD | -1.10% | -7.07% | -40.04% |
Financials (USD)
Sales 2024 * | 216M | Sales 2025 * | 302M | Capitalization | 410M |
---|---|---|---|---|---|
Net income 2024 * | -234M | Net income 2025 * | -161M | EV / Sales 2024 * | 2.45 x |
Net Debt 2024 * | 118M | Net Debt 2025 * | 69.33M | EV / Sales 2025 * | 1.59 x |
P/E ratio 2024 * |
-1.8
x | P/E ratio 2025 * |
-2.89
x | Employees | 380 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.81% |
Latest transcript on Travere Therapeutics, Inc.
1 day | -1.10% | ||
1 week | -7.07% | ||
Current month | -30.09% | ||
1 month | -29.91% | ||
3 months | -41.09% | ||
6 months | -22.67% | ||
Current year | -40.04% |
Managers | Title | Age | Since |
---|---|---|---|
Eric Dube
CEO | Chief Executive Officer | 51 | 19-01-03 |
Chris Cline
DFI | Director of Finance/CFO | 40 | 14-07-31 |
Jula Inrig
CTO | Chief Tech/Sci/R&D Officer | 49 | 22-01-03 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tim Coughlin
BRD | Director/Board Member | 57 | 15-03-30 |
Jeffrey Meckler
BRD | Director/Board Member | 57 | 14-10-07 |
Suzanne Bruhn
BRD | Director/Board Member | 60 | 20-04-07 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.15% | 0 M€ | 0.00% | - | |
0.12% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 5.39 | -1.10% | 1,481,375 |
24-04-24 | 5.45 | -5.05% | 2,777,757 |
24-04-23 | 5.74 | -1.88% | 1,764,302 |
24-04-22 | 5.85 | +2.27% | 1,098,084 |
24-04-19 | 5.72 | -1.38% | 946,781 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.04% | 415M | |
-2.26% | 104B | |
+1.41% | 97.42B | |
+0.79% | 22.2B | |
-17.84% | 21.23B | |
-11.11% | 18.33B | |
-42.83% | 16.35B | |
-17.63% | 15.06B | |
+4.55% | 13.98B | |
+32.11% | 11.66B |
- Stock Market
- Equities
- TVTX Stock